Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Pamiparib |
Trade Name | |
Synonyms | BGB-290|BGB290 |
Drug Descriptions |
Pamiparib (BGB-290) inhibits PARP1 and PARP2, potentially resulting in increased sensitivity to DNA damaging agents (AACR; 2015. Abstract nr 1651, PMID: 32652442). |
DrugClasses | PARP Inhibitor (Pan) 31 |
CAS Registry Number | 1446261-44-4 |
NCIT ID | C120553 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Pamiparib | Bevacizumab Pamiparib | 0 | 0 |
Cabozantinib + Pamiparib | Cabozantinib Pamiparib | 0 | 1 |
Fluorouracil + Hydroxyurea + Pamiparib + Tislelizumab | Fluorouracil Hydroxyurea Pamiparib Tislelizumab | 0 | 1 |
Olaparib + Pamiparib + Temozolomide | Olaparib Pamiparib Temozolomide | 0 | 1 |
Pamiparib | Pamiparib | 2 | 5 |
Pamiparib + Radiotherapy | Pamiparib Radiotherapy | 1 | 0 |
Pamiparib + Temozolomide | Pamiparib Temozolomide | 0 | 6 |
Pamiparib + Tislelizumab | Pamiparib Tislelizumab | 0 | 3 |